Selected References
- Agache I, et al. 2020. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 75(5):1023-1042.
- Manetz S, et al. 2020. Successful pregnancy in setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract. S2213-2198(20)31335-0.
- Middleton PG, et al. 2020. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 55:1901208.
- National Center for Biotechnology Information. «PubChem Compound Summary for , Benralizumab» PubChem, Accessed 7 Oct 2024.
- S. Food and Drug Administration. 2024. Fasenra® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. Accessed on 9 Dec 2024.
